Cannabis Science Targets Successful Autism Treatments and Brings Family Autism Advocate Mieko Hester-Perez on Its Scientific Advisory Board

Warning message

The subscription service is currently unavailable. Please try again later.

Mieko Leads the Charge for Autism Treatment Advocacy as CBIS Initiates Cannabinoid Efficacy Testing to Spotlight Successful Treatments

COLORADO SPRINGS, CO -- Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, today announced its next critical ailment target is autism and brings Mieko Hester-Perez on its Scientific Advisory Board to lead this charge. Mieko gained significant recognition for bringing her son's success with medical cannabis to the public and birthing the significant "Joey's Strain." The Company has begun preliminary protocols to initiate formal studies with Mieko on autism in adults and children spotlighting successful treatments using cannabinoids.

Please visit http://www.miekosblog.com to watch and learn from Mieko's incredible journey with her son Joey. Mieko used medical cannabis to treat her son "Joey" with autism symptoms, and has seen great progress since starting the treatment. As an autism advocate for the new cannabis patient base special needs...

Rate this article: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.